Bienville Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Bienville Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-6,780	Closed	-$776K	–	86
2015 Q1	$776K	Buy	6,780 +1,272	+23%	+$140K	0.45%	23
2014 Q4	$557K	Buy	+5,508	New	+$535K	0.46%	36

Other funds holding IBB

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Bienville Capital Management's IBB Position: Q2 2015 in Review

Bienville Capital Management sold out of iShares Biotechnology ETF (IBB) in Q2 2015, closing a stake of 6,780 shares — an estimated $776K sold.

Bienville Capital Management first reported a position in IBB in Q4 2014 and held it in 2 quarters. The position peaked at $776K in Q1 2015. 420 funds tracked by Wall St. Rank hold IBB as of Q2 2015.

Bienville Capital Management reported no remaining iShares Biotechnology ETF position as of Q2 2015 after selling out during the quarter.
Bienville Capital Management sold 6,780 iShares Biotechnology ETF shares in Q2 2015, an estimated $776K.
Bienville Capital Management first reported a position in iShares Biotechnology ETF in Q4 2014 and held it in 2 quarters.
Bienville Capital Management's iShares Biotechnology ETF position peaked at $776K in Q1 2015.
420 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2015.

Based on Bienville Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.